Penserra Capital Management LLC Affimed N.V. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$5.37 - $7.07 $14,606 - $19,230	-2,720 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $55 - $75	10 Added 0.37%	2,720 $16,000
Q2 2021 Aug 12, 2021	BUY	$7.78 - $11.4 $816 - $1,197	105 Added 4.03%	2,710 $23,000
Q1 2021 May 13, 2021	BUY	$5.12 - $8.48 $2,534 - $4,197	495 Added 23.46%	2,605 $20,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $4,405 - $9,799	1,394 Added 194.69%	2,110 $12,000
Q3 2020 Nov 13, 2020	BUY	$3.26 - $4.73 $2,334 - $3,386	716 New	716 $2,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.